Demographic characteristics of the 21 participants within Singapore Gastric Cancer Epidemiology and Molecular Genetics Programme who developed early gastric neoplasia (EGN)
| SN | Time to event from index gastroscopy (months) | EGN diagnosis (Stage) | EGN resection modality | Baseline atrophic gastritis | Baseline OLGIM | Baseline GIM subtype | Age at index endoscopy | Gender | Low SES | Alcohol consumption | Smoking (pack years) | First-degree relative with GC | History of HP infection | History of peptic ulcer disease | Serum pepsinogen ratio | Serum TFF3 | Serum MIF |
| 1 | 0.0 | High grade dysplasia | EMR | Present | OLGIM II | Complete | 75.0 | Male | Yes | Present | 0–20 | No | Absent | Gastric ulcer | 0.52 | 16.6 | 14.5 |
| 2 | 0.0 | High grade dysplasia | Subtotal Gastrectomy | Present | OLGIM IV | Incomplete | 72.0 | Male | Yes | Absent | >20 | No | Absent | Absent | 4.11 | 7.1 | 63.2 |
| 3 | 0.0 | High grade dysplasia | Subtotal Gastrectomy | Present | OLGIM II | Incomplete | 58.0 | Male | No | Present | >20 | Yes | Present | Gastric ulcer | 3.68 | 7.1 | 22.0 |
| 4 | 6.0 | High grade dysplasia | None | Present | OLGIM III | Incomplete | 59.0 | Male | Yes | Absent | >20 | No | Present | Duodenal ulcer | 8.33 | 16.4 | 41.3 |
| 5 | 12.2 | High grade dysplasia | None | Absent | Absent | 50.0 | Female | No | Absent | 0 | No | Present | Absent | 5.68 | 6.1 | 22.9 | |
| 6 | 12.7 | Intestinal adenocarcinoma (stage IA) | Total gastrectomy | Absent | OLGIM III | Incomplete | 57.0 | Male | Yes | Present | >20 | No | Present | Absent | 5.55 | 9.2 | 27.8 |
| 7 | 13.6 | Diffuse adenocarcinoma (stage IB) | Subtotal gastrectomy | Absent | Absent | 55.0 | Female | No | Absent | 0 | No | Present | Gastric ulcer | 3.71 | 3.6 | 15.3 | |
| 8 | 14.9 | High grade dysplasia | ESD | Present | OLGIM III | Incomplete | 51.0 | Male | No | Absent | 0 | No | Present | Absent | 4.43 | 5.5 | 56.9 |
| 9 | 16.6 | Intestinal adenocarcinoma (stage IA) | Total gastrectomy | Absent | OLGIM I | 68.0 | Male | Yes | Absent | 0 | No | Present | Absent | 3.72 | 5.8 | 42.9 | |
| 10 | 17.4 | High grade dysplasia | ESD | Present | OLGIM III | Incomplete | 77.0 | Female | Yes | Absent | 0 | No | Absent | Gastric ulcer | 7.76 | 10.5 | 23.6 |
| 11 | 18.7 | High grade dysplasia | None | Absent | Absent | 66.0 | Female | Yes | Absent | 0 | No | Absent | Gastric ulcer | 0.44 | 13.7 | 52.8 | |
| 12 | 22.7 | High grade dysplasia | ESD | Absent | OLGIM III | Incomplete | 74.0 | Female | Yes | Absent | 0 | Yes | Present | Absent | 5.86 | 10.0 | 14.4 |
| 13 | 24.4 | High grade dysplasia | EMR | Absent | OLGIM I | 69.0 | Male | No | Absent | 0–20 | No | Absent | Absent | 0.12 | 12.8 | 16.1 | |
| 14 | 24.6 | High grade dysplasia | None | Present | OLGIM IV | Incomplete | 75.0 | Male | Yes | Absent | 0–20 | No | Absent | Absent | 2.27 | 7.6 | 20.2 |
| 15 | 27.7 | Intestinal adenocarcinoma (stage IB) | Total gastrectomy | Present | OLGIM IV | Incomplete | 51.0 | Male | No | Present | 0–20 | No | Absent | Absent | 4.10 | 5.8 | 22.3 |
| 16 | 28.5 | Intestinal adenocarcinoma (stage IA) | ESD | Present | OLGIM II | Incomplete | 59.0 | Male | No | Present | >20 | No | Present | Gastric ulcer | 2.71 | 4.6 | 14.0 |
| 17 | 44.8 | High grade dysplasia | EMR | Present | OLGIM III | Incomplete | 69.0 | Male | No | Present | 0 | No | Present | Absent | 8.97 | 4.7 | 11.2 |
| 18 | 48.1 | High grade dysplasia | EMR | Absent | OLGIM I | 62.0 | Male | No | Present | 0 | No | Present | Gastric ulcer | 8.00 | 3.9 | 30.6 | |
| 19 | 50.7 | Intestinal adenocarcinoma (stage IA) | ESD | Present | OLGIM II | Incomplete | 72.0 | Female | Yes | Absent | 0 | No | Present | Absent | 2.48 | 5.1 | 86.9 |
| 20 | 50.7 | Intestinal adenocarcinoma (stage IA) | ESD | Absent | OLGIM II | Complete | 60.0 | Male | No | Present | >20 | No | Present | Absent | 7.68 | 16.5 | 18.6 |
| 21 | 73.3 | Intestinal adenocarcinoma (stage IA) | ESD | Present | OLGIM II | Incomplete | 67.0 | Female | No | Absent | 0 | Yes | Present (non-eradicated) | Absent | 5.20 | 9.8 | 20.0 |
EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; GC, gastric cancer; MIF, macrophage migration inhibitory factor; OLGIM, Operative Link on Gastric Intestinal Metaplasia; SES, socioeconomic status; TFF3, trefoil factor 3.